P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

Bibliographic Details
Main Authors:	Justin M. Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro Vannucchi, Prithviraj Bose, Rosa Ayala Diaz, Anna B. Halpern, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971116.17929.06

Similar Items

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS
by: Prithviraj Bose, et al.
Published: (2023-08-01)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
by: Pankit Vachhani, et al.
Published: (2023-08-01)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
by: Manman Deng, et al.
Published: (2023-10-01)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
by: Francesca Palandri, et al.
Published: (2023-08-01)

Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
by: Pankit Vachhani, et al.
Published: (2014-01-01)

MF management
by: Prithviraj Bose, et al.
Published: (2019-06-01)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
by: Tracy Clevenger, et al.
Published: (2023-08-01)

Limber Neurons for a Nimble Mind
by: Miller, Earl K., et al.
Published: (2016)

Competitors limber up for the brain games.
by: Speck, Ivan, author
Published: (1997)

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
by: John Mascarenhas, et al.
Published: (2023-08-01)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
by: Michael Loschi, et al.
Published: (2023-08-01)

Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018
by: Joseph D Clark, et al.
Published: (2020-05-01)

Prediction of Ground Wave Propagation Delay for MF R-Mode
by: Niklas Hehenkamp, et al.
Published: (2024-01-01)

The N5K challenge: non-limber integration for LSST cosmology
by: Leonard, CD, et al.
Published: (2023)

The N5K Challenge: Non-Limber Integration for LSST Cosmology
by: C. Danielle Leonard, et al.
Published: (2023-02-01)

The N5K Challenge: Non-Limber Integration for LSST Cosmology
by: C. Danielle Leonard, et al.
Published: (2023-02-01)

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
by: John O. Mascarenhas, et al.
Published: (2017-02-01)

Laser surface cleaning of EN1055 steel
by: Leong, Jin Xiong
Published: (2019)

Multivariate-From-Univariate MCMC Sampler: The R Package MfUSampler
by: Alireza S. Mahani, et al.
Published: (2017-06-01)

LimberJack.jl: auto-differentiable methods for angular power spectra analyses
by: Ruiz-Zapatero, J, et al.
Published: (2024)

LimberJack.jl: auto-differentiable methods for angular power spectra analyses
by: Jaime Ruiz-Zapatero, et al.
Published: (2024-02-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
by: Aaron T. Gerds, et al.
Published: (2023-08-01)

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN
by: Lucia Mazzacurati, et al.
Published: (2019-11-01)

Skywave Detection and Mitigation for the MF R-Mode Continuously Operating Reference Station
by: Pyo-Woong Son, et al.
Published: (2023-05-01)

movMF: An R Package for Fitting Mixtures of von Mises-Fisher Distributions
by: Kurt Hornik, et al.
Published: (2014-07-01)

Evaluation of an Information Flow Gain Algorithm for Microsensor Information Flow in Limber Motor Rehabilitation
by: Naiqiao Ning, et al.
Published: (2021-01-01)

Carbon Costs of Constitutive and Expressed Resistance to a Non-Native Pathogen in Limber Pine.
by: Patrick J Vogan, et al.
Published: (2016-01-01)

Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis
by: Gemma D. Banham, et al.
Published: (2022-05-01)

Limber Pine (Pinus flexilis James), a Flexible Generalist of Forest Communities in the Intermountain West.
by: Marcella A Windmuller-Campione, et al.
Published: (2016-01-01)

Fine dissection of limber pine resistance to Cronartium ribicola using targeted sequencing of the NLR family
by: Jun-Jun Liu, et al.
Published: (2021-07-01)

Further study of laser surface treatment of AISI 1055 steel
by: Tan, Yan Ming
Published: (2019)

Effect of Microstructure on Mechanical Properties of BA1055 Bronze Castings
by: Łabanowski J., et al.
Published: (2014-06-01)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
by: Nico Gagelmann, et al.
Published: (2023-08-01)

Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
by: Adrián Mosquera‐Orgueira, et al.
Published: (2024-03-01)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
by: S. Opat, et al.
Published: (2022-06-01)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
by: F. Stegelmann, et al.
Published: (2022-06-01)

Laser surface hardening of AISI 1055 steel in water submerged condition
by: Zhou, Wei, et al.
Published: (2019)

Az 1055. évi Tihanyi Alapítólevél személy- és helyneveinek eredetéről
by: Katalin Fehértói
Published: (2006-12-01)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
by: S. Verstovsek, et al.
Published: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)